Promising CAR-T therapy trial for lymphoma withdrawn before it began
NCT ID NCT05312476
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to test a new CAR-T cell therapy that targets a protein called Igβ on cancer cells in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The trial planned to enroll patients who had already tried at least two other treatments. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR-T cells targeting Igβ
- What this could lead to
- If successful, this approach could offer a new treatment option for patients with hard-to-treat B-cell non-Hodgkin's lymphoma.
- What could go wrong
- The trial was withdrawn before enrolling any participants, so no data exists. CAR-T therapies carry risks like severe immune reactions and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGΒ-POSITIVE REFRACTORY RELAPSED NON-HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.